Urinary Aquaporin 2 as a Potential Indicator Predicting Tolvaptan Response in Patients With ADPKD

INTRODUCTION: Tolvaptan is used to treat autosomal dominant polycystic kidney disease (ADPKD) because it inhibits binding of the antidiuretic hormone vasopressin to the vasopressin V2 receptor (V2R), which suppresses the insertion of preformed water channel aquaporin 2 (AQP2) molecules in the lumina...

Descripción completa

Detalles Bibliográficos
Autores principales: Makabe, Shiho, Manabe, Shun, Kataoka, Hiroshi, Akihisa, Taro, Yoshida, Rie, Ushio, Yusuke, Sato, Masayo, Tsuchiya, Ken, Mochizuki, Toshio, Nitta, Kosaku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418978/
https://www.ncbi.nlm.nih.gov/pubmed/34514204
http://dx.doi.org/10.1016/j.ekir.2021.06.033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418978/
https://www.ncbi.nlm.nih.gov/pubmed/34514204
http://dx.doi.org/10.1016/j.ekir.2021.06.033

Ejemplares similares